# Ophthalmology Sector Canonical URL: https://biopharmsignal.com/sector/ophthalmology Ophthalmology includes companies developing therapies, devices, and diagnostics for diseases of the eye, including retinal disorders, glaucoma, dry eye, and surgical vision care. This page groups businesses exposed to both therapeutic and procedure-driven eye care markets. Companies currently grouped under Ophthalmology: 28 ## Recent Sector News - 2026-09-09 12:00 EST — PRQR — [ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026](https://biopharmsignal.com/news/PRQR/proqr-announces-first-participant-dosed-in-phase-1-study-of-ax-0811-and-virtual--c23f0426) — Source: ProQR Therapeutics - 2026-09-09 11:00 EST — OKYO — [OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026](https://biopharmsignal.com/news/OKYO/okyo-pharma-to-present-at-ophthalmology-futures-european-forum-and-inovation-day-c84eca37) — Source: OKYO Pharma - 2026-09-08 12:00 EST — LCTX — [Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-announces-issuance-of-patent-underlying-its-alloscope--6bd717c1) — Source: Lineage Cell Therapeutics - 2026-09-08 11:00 EST — KPRX — [Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-appoints-keith-j-lane-as-executive-vice-president-of-globa-9bcc5a1e) — Source: Kiora Pharmaceuticals - 2026-09-08 11:00 EST — OKYO — [OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference](https://biopharmsignal.com/news/OKYO/okyo-pharma-to-participate-in-a-fireside-chat-at-the-cantor-global-healthcare-co-bfb52aa8) — Source: OKYO Pharma - 2026-09-08 10:00 EST — BLTE — [Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1](https://biopharmsignal.com/news/BLTE/belite-bio-announces-submission-of-new-drug-application-to-the-ministry-of-healt-0719ad31) — Source: Belite Bio - 2026-09-04 12:39 EST — TARS — [Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care](https://biopharmsignal.com/news/TARS/tarsus-pharmaceuticals-completes-acquisition-of-alkeus-pharmaceuticals-expanding-8c5bcd65) — Source: Tarsus Pharmaceuticals - 2026-09-02 12:00 EST — PRQR — [ProQR to Participate in Upcoming Investor Conferences in September 2026](https://biopharmsignal.com/news/PRQR/proqr-to-participate-in-upcoming-investor-conferences-in-september-2026-90d68b03) — Source: ProQR Therapeutics - 2026-09-02 11:00 EST — EYPT — [EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting](https://biopharmsignal.com/news/EYPT/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-19788f9f) — Source: EyePoint Pharmaceuticals - 2026-09-01 20:30 EST — TARS — [Tarsus to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/TARS/tarsus-to-participate-in-upcoming-investor-conferences-10603b1f) — Source: Tarsus Pharmaceuticals - 2026-09-01 20:05 EST — SGHT — [Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15](https://biopharmsignal.com/news/SGHT/sight-sciences-to-present-at-the-upcoming-morgan-stanley-global-healthcare-confe-a434ea36) — Source: Sight Sciences - 2026-09-01 12:00 EST — BLTE — [Belite Bio to Participate in Four Upcoming Investor Conferences](https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-four-upcoming-investor-conferences-51ee4768) — Source: Belite Bio - 2026-09-01 11:02 EST — OCGN — [Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration](https://biopharmsignal.com/news/OCGN/ocugen-announces-first-patient-dosed-in-phase-3-registrational-trial-of-ocu410-m-5728a6d6) — Source: Ocugen - 2026-09-01 11:00 EST — HROW — [Harrow to Participate in Three Investor Conferences in September](https://biopharmsignal.com/news/HROW/harrow-to-participate-in-three-investor-conferences-in-september-90b721c9) — Source: Harrow, Inc. - 2026-09-01 11:00 EST — OCUL — [Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences](https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-participate-in-september-and-october-investor-and-scientif-73e60316) — Source: Ocular Therapeutix - 2026-08-27 20:05 EST — OTLK — [Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-appoints-kevin-lundquist-as-chief-financial-officer-as-it-p-bcce914f) — Source: Outlook - 2026-08-27 13:01 EST — OTLK — [Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-ceo-bob-jahr-participates-in-the-virtual-investor-why-now-o-eb0c7a49) — Source: Outlook - 2026-08-25 11:02 EST — OCGN — [Ocugen to Participate in Upcoming September Investor and Industry Conferences](https://biopharmsignal.com/news/OCGN/ocugen-to-participate-in-upcoming-september-investor-and-industry-conferences-16cf3119) — Source: Ocugen - 2026-08-24 20:00 EST — BLTE — [Belite Bio to Host Virtual Commercial Day on September 2, 2026](https://biopharmsignal.com/news/BLTE/belite-bio-to-host-virtual-commercial-day-on-september-2-2026-46c4b01b) — Source: Belite Bio - 2026-08-24 08:00 EST — OCS — [First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis](https://biopharmsignal.com/news/OCS/first-patient-treated-in-pioneer-1-registrational-trial-of-privosegtor-for-optic-d34daa6c) — Source: Oculis ## Companies - [ADVM](https://biopharmsignal.com/company/ADVM) — Adverum Biotechnologies - [ALC](https://biopharmsignal.com/company/ALC) — Alcon Inc. - [ALDX](https://biopharmsignal.com/company/ALDX) — Aldeyra Therapeutics, Inc. - [ALIM](https://biopharmsignal.com/company/ALIM) — Alimera Sciences - [BLTE](https://biopharmsignal.com/company/BLTE) — Belite Bio - [CLSD](https://biopharmsignal.com/company/CLSD) — Clearside Biomedical - [EYEN](https://biopharmsignal.com/company/EYEN) — Eyenovia - [EYPT](https://biopharmsignal.com/company/EYPT) — EyePoint Pharmaceuticals - [GKOS](https://biopharmsignal.com/company/GKOS) — Glaukos Corporation - [GRAY](https://biopharmsignal.com/company/GRAY) — Graybug - [GHSI](https://biopharmsignal.com/company/GHSI) — Guardion Health Sciences - [HROW](https://biopharmsignal.com/company/HROW) — Harrow, Inc. - [IRIX](https://biopharmsignal.com/company/IRIX) — IRIDEX - [KPRX](https://biopharmsignal.com/company/KPRX) — Kiora Pharmaceuticals - [KOD](https://biopharmsignal.com/company/KOD) — Kodiak Sciences - [LENZ](https://biopharmsignal.com/company/LENZ) — Lenz Therapeutics Inc - [LCTX](https://biopharmsignal.com/company/LCTX) — Lineage Cell Therapeutics - [MGTX](https://biopharmsignal.com/company/MGTX) — MeiraGTx - [OCGN](https://biopharmsignal.com/company/OCGN) — Ocugen - [OCUL](https://biopharmsignal.com/company/OCUL) — Ocular Therapeutix - [OCS](https://biopharmsignal.com/company/OCS) — Oculis - [OCUP](https://biopharmsignal.com/company/OCUP) — Ocuphire - [OKYO](https://biopharmsignal.com/company/OKYO) — OKYO Pharma - [OTLK](https://biopharmsignal.com/company/OTLK) — Outlook - [PRQR](https://biopharmsignal.com/company/PRQR) — ProQR Therapeutics - [SGHT](https://biopharmsignal.com/company/SGHT) — Sight Sciences - [TARS](https://biopharmsignal.com/company/TARS) — Tarsus Pharmaceuticals - [VRDN](https://biopharmsignal.com/company/VRDN) — Viridian Therapeutics